Factors associated with quality of life measured by EQ-5D in patients with nontuberculous mycobacterial pulmonary disease
- 285 Downloads
The impact of pulmonary nontuberculous mycobacterial (pNTM) disease on health-related quality of life (HRQoL) has not received significant attention in the literature. In this study, we compared the HRQoL in patients with pNTM disease and healthy subjects and identified influencing factors using EuroQol 5D (EQ-5D) data.
The present study used an age- and sex-matched case–control analysis from a cohort of 85 pNTM patients and 340 participants from a national survey. Baseline EQ-5D utility scores and EQ-5D visual analog scale (VAS) scores were measured in both groups. In patients with pNTM disease, the factors affecting EQ-5D were identified using multiple linear regression analysis.
While the median EQ-5D VAS scores were lower in pNTM patients than in the control subjects (pNTM, 70; control, 80; P < 0.001), the median EQ-5D utility scores were similar in two groups (both, 1.000, P = 0.878). Interestingly, the percentage of subjects reporting problems on the anxiety/depression dimension was higher for patients with pNTM disease (18.8 %) compared with the control subjects (11.5 %, P = 0.07). In multivariate analysis, increasing severity of forced expired volume in one second (FEV1) decline was associated with a significant decrease in EQ-5D scores of pNTM patients.
This study suggested the EQ-5D may not be useful instrument in pNTM patients due to ceiling effect of EQ-5D and mild disease activity. Patients with pNTM disease tended to report more reduced health status and more problems with anxiety/depression than the healthy controls. Lung function, measured by FEV1, was independently associated with EQ-5D scores in patients with pNTM disease.
KeywordsNontuberculous mycobacterium Quality of life EQ-5D
This work was supported by a National Research Foundation of Korea Grant funded by the Korean Government (2011-0013018).
Conflict of interest
Authors have no conflict of interest including financial, personal, academic and intellectual.
- 1.Prevots, D. R., Shaw, P. A., Strickland, D., Jackson, L. A., Raebel, M. A., Blosky, M. A., et al. (2010). Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. American Journal of Respiratory and Critical Care Medicine, 182(7), 970–976.PubMedCentralPubMedCrossRefGoogle Scholar
- 2.Winthrop, K. L., McNelley, E., Kendall, B., Marshall-Olson, A., Morris, C., Cassidy, M., et al. (2010). Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: An emerging public health disease. American Journal of Respiratory and Critical Care Medicine, 182(7), 977–982.PubMedCrossRefGoogle Scholar
- 3.Griffith, D. E., Aksamit, T., Brown-Elliott, B. A., Catanzaro, A., Daley, C., Gordin, F., et al. (2007). An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. American Journal of Respiratory and Critical Care Medicine, 175(4), 367–416.PubMedCrossRefGoogle Scholar
- 12.Chung, M. J., Lee, K. S., Koh, W. J., Lee, J. H., Kim, T. S., Kwon, O. J., et al. (2005). Thin-section CT findings of nontuberculous mycobacterial pulmonary diseases: Comparison between Mycobacterium avium-intracellular complex and Mycobacterium abscessus infection. Journal of Korean Medical Science, 20(5), 777–783.PubMedCentralPubMedCrossRefGoogle Scholar
- 21.Khan, Z., Miller, A., Bachan, M., & Donath, J. (2010). Mycobacterium avium complex (MAC) lung disease in two inner city community hospitals: Recognition, prevalence, co-infection with Mycobacterium tuberculosis (MTB) and pulmonary function (PF) improvements after treatment. The Open Respiratory Medicine Journal, 4, 76–81.PubMedCentralPubMedCrossRefGoogle Scholar
- 26.Puhan, M. A., Guyatt, G. H., Goldstein, R., Mador, J., McKim, D., Stahl, E., et al. (2007). Relative responsiveness of the Chronic Respiratory Questionnaire, St. Georges Respiratory Questionnaire and four other health-related quality of life instruments for patients with chronic lung disease. Respiratory Medicine, 101(2), 308–316.PubMedCrossRefGoogle Scholar
- 30.Huang, C. T., Tsai, Y. J., Wu, H. D., Wang, J. Y., Yu, C. J., Lee, L. N., et al. (2012). Impact of non-tuberculous mycobacteria on pulmonary function decline in chronic obstructive pulmonary disease. The International Journal of Tuberculosis and Lung Disease, 16(4), 539–545.PubMedCrossRefGoogle Scholar